GCGR - glucagon receptor Gene

Also Known as GGR; GL-R; MVAH

Species: Homo sapiens

Gene Type: protein coding
Gene ID: 2642

About GCGR

Cytogenetic location: 17q25.3 Genomic coordinates (GRCh38): 17:81,804,150-81,814,008 (from NCBI)

This gene has 6 transcripts (splice variants), 1 gene allele, 184 orthologues, 42 paralogues and is associated with 2 phenotypes. Biased expression in liver (RPKM 10.3), kidney (RPKM 5.0) and 1 other tissue.

Summary

The protein encoded by this gene is a Glucagon Receptor that is important in controlling blood glucose levels. Defects in this gene are a cause of non-insulin-dependent diabetes mellitus (NIDDM).[provided by RefSeq, Jan 2010]

GCGR Products (4)

mRNA Protein Name
XM_006722277.2 XP_006722340.1 glucagon receptor isoform X1
NM_000160.5 NP_000151.1 glucagon receptor precursor
XM_011523539.2 XP_011521841.1 glucagon receptor isoform X3
XM_017024446.2 XP_016879935.1 glucagon receptor isoform X2

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables glucagon receptor activity IDA
IDA: Inferred from direct assay
9287038 GOA
Biological Process GO Annotation Evidence References Source
involved in adenylate cyclase-activating G protein-coupled receptor signaling pathway IDA
IDA: Inferred from direct assay
28514451 GOA
involved in adenylate cyclase-modulating G protein-coupled receptor signaling pathway IMP
IMP: Inferred from mutant phenotype
9287038 GOA
involved in cellular response to glucagon stimulus IDA
IDA: Inferred from direct assay
9287038 GOA
Cellular Component GO Annotation Evidence References Source
located in plasma membrane IDA
IDA: Inferred from direct assay
9287038 GOA
located in plasma membrane IMP
IMP: Inferred from mutant phenotype
28514451 GOA
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

GCGR Protein Structure

HRM

HRM: Hormone receptor domain (56 - 122)

7tm_2

7tm_2: 7 transmembrane receptor (Secretin family) (139 - 396)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 477 a.a.
Protein Preferred Names Protein Names

glucagon receptor

Recombinant GCGR Proteins

Cat. No. Product Name Accession Purity
HY-P700411 GCGR Protein, Human (HEK293, N-His, C-Myc) P47871 (A26-K136) ≥ 95%, as determined by reducing SDS-PAGE.

GCGR Antibodies

Cat. No. Product Name Application Reactivity
HY-P810878 Glucagon Receptor Antibody WB, ICC/IF Human, Mouse, Rat

Related Diseases

Diseases Alias
Endocrine Pancreas Disease

  • Disorder Of Endocrine Pancreas
Type 2 Diabetes Mellitus

  • Insulin Resistance

  • NIDDM

  • Diabetes Mellitus, Non-Insulin-Dependent

  • Type 2 Diabetes

  • T2D

  • Noninsulin-Dependent Diabetes Mellitus

  • Diabetes Mellitus, Type Ii

  • Maturity-Onset Diabetes

  • Insulin Resistance, Severe, Digenic

  • Diabetes Mellitus, Type 2

  • Diabetes Mellitus, Noninsulin-Dependent

  • Diabetes Mellitus, Noninsulin-Dependent, Association With

  • Diabetes Mellitus, Noninsulin-Dependent, Late Onset

  • Hypertension, Insulin Resistance-Related, Susceptibility To

  • Insulin Resistance, Susceptibility To

  • Non-Insulin-Dependent Diabetes Mellitus

  • Type Ii Diabetes Mellitus

  • Adult-Onset Diabetes Mellitus

  • Maturity-Onset Diabetes Mellitus

  • Diabetes Mellitus Type 2

  • Type Ii Diabetes

  • Type 2 Diabetes Mellitus, Susceptibility To

  • Diabetes, Type 2

  • Diabetes Mellitus, Noninsulin-Dependent, Susceptibility To

  • Diabetes Mellitus, Non-Insulin-Dependent, Susceptibility To

  • Diabetes Mellitus, Type 2, Susceptibility To

  • Diabetes Mellitus, Noninsulin-Dependent, 2

  • Diabetes Mellitus, Type Ii, Susceptibility To

  • Hypertension, Insulin Resistance-Related

  • Adult-Onset Diabetes

  • Aodm

  • Diabetes Mellitus, Adult-Onset

  • Diabetes Mellitus Type Ii

  • Diabetes Mellitus Type 2, Susceptibility To

  • Diabetes, Type Ii, Susceptibility To

  • Diabetes Type 2

  • Diabetes Mellitus

  • Adult Onset Diabetes

  • Maturity Onset Diabetes

  • Nonketotic Diabetes

  • Non-Insulin Dependent Diabetes Mellitus

  • T2dm - [Type 2 Diabetes Mellitus]

  • Niddm - [Non Insulin Dependent Diabetes Mellitus]

  • Dm2

  • Dm Type Ii

  • Diabetic Type 2

  • Insulin Requiring Type 2 Diabetes

  • Noninsulin Dependent Diabetes

  • Non-Insulin-Dependent Diabetes Mellitus Without Complications

  • Diabetes Due To Insulin Secretory Defect

  • Diabetes Mellitus Due To Insulin Secretory Defect

  • Non-Insulin-Dependent Diabetes Of The Young

  • Senile Diabetes

  • Nonketotic Hyperglycaemia

  • Stable Diabetes
Pheochromocytoma

  • Pheochromocytoma, Susceptibility To

  • Phaeochromocytoma

  • Adrenal Gland Chromaffin Paraganglioma

  • Adrenal Gland Chromaffinoma

  • Adrenal Gland Paraganglioma

  • Adrenal Gland Pheochromocytoma

  • Chromaffin Paraganglioma Of The Adrenal Gland

  • Intraadrenal Paraganglioma

  • PCC

  • Chromaffin Cell Tumor

  • Medullary Chromaffinoma

  • Medullary Paraganglioma

  • Pheochromoblastoma

  • Pheochromocytomas

  • Chromaffin Cell Neoplasm

  • Pheochromocytoma, Malignant
Hyperglycemia
Hypoglycemia

  • Hypoglycaemia

  • Low Blood Sugar

  • Hypoglycaemia Nos

  • Spontaneous Hypoglycaemia

  • Nondiabetic Hypoglycaemia

  • Hypoglycaemic Disorder Nos

  • Hypoglycaemic Syndrome
Epiphyseal Chondrodysplasia, Miura Type

  • ECDM

  • Tall Stature-Scoliosis-Macrodactyly Of The Great Toes Syndrome

  • Miura Type Epiphyseal Chondrodysplasia

  • Tall Stature-Scoliosis-Macrodactyly Of The Halluces Syndrome

  • Tall Stature-Long Halluces-Multiple Extra-Epiphyses Syndrome

  • Chondrodysplasia, Epiphyseal, Miura Type
Body Mass Index Quantitative Trait Locus 11

  • OBESITY

  • Obesity, Susceptibility To

  • Leanness, Inherited

  • Obesity, Susceptibility To, Bmiq11

  • Obesity, Mild, Early-Onset

  • Obesity, Association With

  • Obesity, Early-Onset, Susceptibility To

  • Obesity, Severe

  • Obesity, Severe, And Type Ii Diabetes

  • Obesity, Late-Onset

  • BMIQ11

  • Obesity Bmiq11

  • Obesity, Early-Onset

  • Obesity , Susceptibility To

  • Simple Obesity Nos

  • Excess Fat

  • Obesity, Not Elsewhere Classified, Body Mass Index Not Elsewhere Classified

  • Adiposis
Hypertension, Essential

  • Essential Hypertension

  • Hypertension

  • High Blood Pressure

  • Hypertension, Essential, Susceptibility To

  • Hypertensive Disease

  • Primary Hypertension

  • EHT

  • Hypertension, Salt-Sensitive Essential, Susceptibility To

  • Hyperpiesia

  • Idiopathic Hypertension

  • Hypertensive Disorder

  • Hypertension, Essential, Susceptibility To, 3

  • Hypertension, Essential 3

  • Hypertension, Essential, Salt-Sensitive

  • Hypertension, Essential, Susceptibility To, 6

  • Hypertension, Essential 6

  • Hypertension, Salt-Sensitive Essential

  • Hypertension, Susceptibility To

  • Hypertension, Essential, Susceptibility To, 4

  • Hypertension, Essential 4

  • Hypertension, Essential, Susceptibility To, 2

  • Hypertension, Essential 2

  • Hypertension, Essential, Susceptibility To, 1

  • Hypertension, Essential 1

  • Hypertension, Essential, Susceptibility To, 5

  • Hypertension, Essential 5

  • Htn

  • Vascular Hypertensive Disorder

  • Systemic Primary Arterial Hypertension

  • Hbp - [High Blood Pressure]

  • Systemic Arterial Hypertensive Disorder

  • Elevated Blood Pressure

  • Arterial Hypertension Nos

  • Hypertension Nos

  • Benign Hypertension

  • Systemic Arterial Hypertension

  • Systemic Hypertension

  • Artery Htn

  • Benign Htn

  • Vascular Htn

  • Vascular Hypertension

  • Cholesterol Hypertension

  • Cholesterol Htn

  • Idiopathic Htn

  • Malignant Hypertension

  • Malignant Htn

  • Raised Blood Pressure

  • Cardiovascular Hypertension

  • Primary Htn - [Hypertension]

  • High Arterial Tension

  • High Blood Pressure Disorder

  • Ht - [Hypertension]

  • Htn - [Hypertension]

  • Hypertensive Vascular Disease

  • Hypertensive Vascular Degeneration
Diabetes Mellitus

  • Diabetes
Prediabetes Syndrome

  • Impaired Glucose Tolerance

  • Prediabetes

  • Prediabetic State

  • IGT

  • Igt - [Impaired Glucose Tolerance]

  • Impaired Glucose Tolerance With Unspecified Complication

  • Impaired Glucose Tolerance Without Complication

  • Abnormal Glucose Tolerance
Mahvash Disease

  • Gcgr-Related Hyperglucagonemia

  • MVAH

  • Alpha-Cell Hyperplasia With Glucagonemia

  • Nesidioblastosis, Alpha Cell Hyperplasia, Microglucagonoma, And Nonfunctioning Islet Cell Tumor

  • Nesidioblastosis Alpha Cell Hyperplasia Microglucagonoma And Nonfunctioning Islet Cell Tumor
Diseases Alias
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (10)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-13443 Exendin-4 Agonist 99.89% Unkown
HY-P0014 Liraglutide Agonist 99.95% Unkown
HY-112185 Orforglipron Agonist 99.64% Unkown
HY-P0082 Glucagon (1-29), bovine, human 99.91% Unkown
HY-P0120 Dulaglutide Agonist 96% Unkown
HY-P0082A Glucagon (1-29), bovine, human hydrochloride 99.89% Unkown
HY-13443A Exendin-4 acetate Agonist 99.87% Unkown
HY-112185A Orforglipron hemicalcium hydrate Agonist 99.58% Unkown
HY-P3469A Dasiglucagon acetate 98.66% Unkown
HY-P3469 Dasiglucagon Agonist / Unkown

Clinical Phase

Bioactive Molecules (17)
Cat. No. Product Name Effect
Purity Phase
HY-P3463 Beinaglutide 98.49% Phase 4
HY-P0165 Taspoglutide Agonist 99.43% Phase 3
HY-P2221B Glepaglutide acetate Agonist 99.48% Phase 3
HY-P4146A Survodutide TFA Agonist 99.39% Phase 3
HY-P2221 Glepaglutide Agonist 99.70% Phase 3
HY-P3375A Mazdutide TFA Agonist 99.67% Phase 3
HY-P3506B Retatrutide acetate Agonist 99.69% Phase 3
HY-112668B Retagliptin hydrochloride / Phase 3
HY-125824 Danuglipron Agonist 99.85% Phase 2
HY-50663 MK 0893 Antagonist 99.83% Phase 2
HY-19904 Adomeglivant Antagonist 99.63% Phase 2
HY-P2231A Cotadutide acetate Agonist 99.30% Phase 2
HY-12525 LGD-6972 Antagonist 98.0% Phase 2
HY-19947 PF-06291874 Antagonist 99.31% Phase 2
HY-P10018 Bamadutide Agonist 99.94% Phase 2
HY-P3498 Elsiglutide Agonist 99.64% Phase 2
HY-19374 BAY-27-9955 Antagonist 99.68% Phase 1
Bioactive MoleculesInhibitory Antibodies (3)
Cat. No. Product Name Effect
Purity Phase
HY-P99383 Volagidemab Antagonist ≥99.0% Phase 2
HY-P99357 Crotedumab Inhibitor 99.22% Phase 1
HY-P992007 PF-06293620 Antagonist / Phase 1

Pre-clinical Phase

Bioactive Molecules (154)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P3506 Retatrutide Agonist 99.96% Unkown
HY-P3375 Mazdutide Agonist 99.97% Unkown
HY-P0054 GLP-1(7-36), amide acetate 99.01% Unkown
HY-121835 GLP-1R agonist 2 Agonist 99.57% Unkown
HY-P4146 Survodutide Agonist 99.99% Unkown
HY-P0054A GLP-1(7-36), amide Agonist 99.90% Unkown
HY-P1141 GLP-1(9-36)amide Antagonist 99.69% Unkown
HY-101116 GLP-1R Antagonist 1 Antagonist 99.67% Unkown
HY-P11274A Zenagamtide sodium Agonist 99.96% Unkown
HY-P3506A Retatrutide TFA Agonist 99.47% Unkown
HY-103546 BETP Agonist 99.48% Unkown
HY-P1024 GLP-2(1-33)(human) Agonist 98.43% Unkown
HY-P0054B GLP-1(7-36), amide TFA 98.82% Unkown
HY-P10736A AMG133 peptide payload TFA Agonist 99.70% Unkown
HY-P1023 VIP(6-28)(human, rat, porcine, bovine) Antagonist 98.09% Unkown
HY-P3366 Ecnoglutide Agonist 99.93% Unkown
HY-P1160 Bay 55-9837 Agonist 99.56% Unkown
HY-124622 NNC-0640 Modulator 98.43% Unkown
HY-P10736 AMG133 peptide payload 99.94% Unkown
HY-129658A TT-OAD2 Agonist 99.59% Unkown
HY-P3291 Dapiglutide Agonist 98.52% Unkown
HY-P2231 Cotadutide Agonist 99.80% Unkown
HY-142162 LSN3318839 Modulator 99.22% Unkown
HY-10930 UNC0321 Inhibitor 99.91% Unkown
HY-P2625 GLP-2(3-33) Agonist 99.82% Unkown
HY-P0150 Glucagon (19-29), human Inhibitor 99.11% Unkown
HY-P0014S1 Liraglutide-13C5,15N tetraTFA Agonist 97.74% Unkown
HY-P1144 Oxyntomodulin (bovine, porcine) Agonist 99.77% Unkown
HY-P3101 GLP-1(28-36)amide 99.18% Unkown
HY-P1145A Glucagon-like peptide 1 (1-37), human TFA Agonist 99.55% Unkown
HY-P1348 GLP-1 moiety from Dulaglutide 99.60% Unkown
HY-116819 VU0453379 Modulator 98.0% Unkown
HY-145632 Pemvidutide Agonist 99.40% Unkown
HY-103547 L-168049 Antagonist 99.94% Unkown
HY-N0630 Shanzhiside methyl ester Agonist 99.97% Unkown
HY-P1143A [Des-His1,Glu9]-Glucagon amide TFA Antagonist 98.36% Unkown
HY-P1141A GLP-1(9-36)amide TFA Antagonist 98.61% Unkown
HY-112679 GLP-1 receptor agonist 2 Agonist 98.70% Unkown
HY-P10032 NN1177 Agonist 99.54% Unkown
HY-P3102 GLP-1(32-36)amide 98.44% Unkown
HY-50675 GRA Ex-25 Inhibitor 99.07% Unkown
HY-141840 GLP-1R modulator C5 Modulator 99.81% Unkown
HY-50159 Glucagon receptor antagonist-3 Antagonist 99.78% Unkown
HY-P10019 Pegsebrenatide Agonist 95.50% Unkown
HY-P5815 GLP-1 (1-36) amide (human, rat) 98.10% Unkown
HY-P10031 SAR441255 Agonist 99.84% Unkown
HY-50158 Glucagon receptor antagonist-2 Antagonist 99.23% Unkown
HY-P3617 Glucagon (22-29) Agonist 98.12% Unkown
HY-141842 GLP-1R modulator L7-028 Modulator 99.47% Unkown
HY-148212 GLP-1R agonist 17 Agonist 99.82% Unkown
HY-P10031A SAR441255 TFA 99.93% Unkown
HY-172811 DA-302168S Agonist 98.01% Unkown
HY-116854 NNC 92-1687 Antagonist 98.74% Unkown
HY-13443B Exendin-4-Lys-azide TFA Agonist 99.84% Unkown
HY-145632A Pemvidutide TFA Antagonist 98.07% Unkown
HY-P11237 Enicepatide Agonist 98.16% Unkown
HY-P5815A GLP-1 (1-36) amide (human, rat) TFA 98.02% Unkown
HY-148844 GCGR antagonist 2 Antagonist 98.17% Unkown
HY-P3622 (Ser8)-GLP-1 (7-36) amide, human Agonist 99.10% Unkown
HY-141839 GLP-1R modulator C16 Modulator 98.67% Unkown
HY-P1145 Glucagon-like peptide 1 (1-37), human Agonist 99.70% Unkown
HY-153476A GIP/GLP-1 dual receptor agonist-1 sodium Agonist 98.33% Unkown
HY-P10032A NN1177 TFA Agonist 99.22% Unkown
HY-P3491 Pegloxenatide Agonist 90.00% Unkown
HY-P1228 HAEGTFT 98.81% Unkown
HY-119739 Skyrin Antagonist 97.0% Unkown
HY-P4146B Survodutide sodium Agonist / Unkown
HY-124803 GPCR modulator-1 Modulator / Unkown
HY-P1224 HAEGTFTSDVS 98.62% Unkown
HY-P1231 GTFTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS 99.03% Unkown
HY-P1543 Exendin-3 Antagonist 99.89% Unkown
HY-116819A VU0453379 hydrochloride Modulator 99.0% Unkown
HY-P1227 SDV-Exendin-3/4 95.96% Unkown
HY-P2497 Exendin (5-39) Antagonist 99.43% Unkown
HY-P1223 Exendin-3/4 (59-86) 98.19% Unkown
HY-P1225 {Val1}-Exendin-3/4 99.45% Unkown
HY-108795B [Gly8]-GLP-1(7-37) acetate Agonist 99.11% Unkown
HY-P1143 [Des-His1,Glu9]-Glucagon amide Antagonist 99.32% Unkown
HY-P5074 GRPP (human) Agonist 98.94% Unkown
HY-147622 GLP-1R agonist 9 Agonist / Unkown
HY-P1226 HAEGTFTSD Agonist 98.48% Unkown
HY-P10341 ZP3022 Agonist 98.00% Unkown
HY-144035 GLP-1R agonist 4 Agonist 98.26% Unkown
HY-P1229 FTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS 98.01% Unkown
HY-142162A (S,R)-LSN3318839 Control 98.25% Unkown
HY-P11274 Zenagamtide Agonist / Unkown
HY-128781 Glucagon receptor antagonist-5 Antagonist / Unkown
HY-138996 GLP-1 receptor agonist 8 Agonist / Unkown
HY-128103 Glucagon receptor antagonist-7 Antagonist / Unkown
HY-P0211 [Ac-Tyr1,D-Phe2]GRF 1-29, amide (human) Antagonist / Unkown
HY-P4843 Gastric Inhibitory Polypeptide (6-30) amide (human) / Unkown
HY-129657 GLP-1 receptor agonist 4 Agonist / Unkown
HY-P3616 Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide / Unkown
HY-P11275 TC4 Agonist / Unkown
HY-P11818 GIPR/GLP-1R/GCGR agonist-1 / Unkown
HY-P3542 Des His1, Glu8 Exendin-4 Antagonist / Unkown
HY-172673 GLP-1R agonist 31 Agonist / Unkown
HY-P5578A A8SGLP-1 TFA Agonist / Unkown
HY-P4503 (D-His1)-Exenatide Control / Unkown
HY-P3053 Helospectin I / Unkown
HY-P1144A Oxyntomodulin (bovine, porcine) TFA Agonist / Unkown
HY-P5578 A8SGLP-1 Agonist / Unkown
HY-P4459 (Des-Gly2)-Exenatide Control / Unkown
HY-P3608 [Des-His1,Glu9] Glucagon Antagonist / Unkown
HY-P11487 UTG-4 Agonist / Unkown
HY-13443F Exendin 4, biotin labeled Agonist / Unkown
HY-129658 TT-OAD2 free base Agonist / Unkown
HY-P3539 Exendin-4 (3-39) / Unkown
HY-144135 GLP-1R agonist 7 Agonist / Unkown
HY-177156 Glucagon receptor antagonist-8 Antagonist / Unkown
HY-P10337 OXM-7 Agonist / Unkown
HY-P2880 PHI-27 (porcine) / Unkown
HY-P3050 Helospectin II Inhibitor / Unkown
HY-P11279 TC2 Agonist / Unkown
HY-P11044 GEP12 Agonist / Unkown
HY-P5161 FC382K10W15 Agonist / Unkown
HY-107129 MK-3577 Antagonist / Unkown
HY-P3621 Biotinyl-Glucagon (1-29), human, bovine, porcine / Unkown
HY-144133 GLP-1R agonist 5 Agonist / Unkown
HY-P0212 Neuropeptide Y, porcine Agonist / Unkown
HY-120401 Glybuzole Activator / Unkown
HY-P1160A Bay 55-9837 TFA / Unkown
HY-P0212A Neuropeptide Y, porcine TFA / Unkown
HY-181709 TPM003 Agonist / Unkown
HY-159696A ISIS 449884 sodium Inhibitor / Unkown
HY-153476 GIP/GLP-1 dual receptor agonist-1 Agonist / Unkown
HY-D3173 TP-α Modulator / Unkown
HY-159696B ISIS 449884 sodium scrambled negative control Inhibitor / Unkown
HY-171851 GLP-1R agonist 32 Agonist / Unkown
HY-P11881 IUB288 Agonist / Unkown
HY-129656 GLP-1 receptor agonist 3 Agonist / Unkown
HY-P2625S1 GLP-2(3-33) (Leu-13C6,15N) TFA Agonist / Unkown
HY-12525B LGD 6972 ammonium Antagonist / Unkown
HY-13443S Exendin-4 (Leu-13C6,15N) TFA / Unkown
HY-169707 GCGR antagonist 3 Antagonist / Unkown
HY-P4672 (Met(O)27)-Glucagon (1-29) (human, rat, porcine) / Unkown
HY-144134 GLP-1R agonist 6 Agonist / Unkown
HY-P3102A GLP-1(32-36)amide TFA / Unkown
HY-P11880 LY3324954 Agonist / Unkown
HY-159696 ISIS 449884 Inhibitor / Unkown
HY-P3101A GLP-1(28-36)amide TFA / Unkown
HY-106559 Sorbinicate Inhibitor / Unkown
HY-172836S GLP-1 receptor agonist 17-d3 Agonist / Unkown
HY-144136 GLP-1R agonist 8 Agonist / Unkown
HY-144033 GLP-1R agonist 1 Agonist / Unkown
HY-P5161A FC382K10W15 TFA Agonist / Unkown
HY-180445 Glucagon receptor antagonist-10 Antagonist / Unkown
HY-12525A LGD-6972 sodium Antagonist / Unkown
HY-125824A Danuglipron tromethamine Agonist / Unkown
HY-12735 SCH 900822 Antagonist / Unkown
HY-180446 Glucagon receptor antagonist-11 Antagonist / Unkown
HY-160281 CCD-2 / Unkown
HY-180444 Glucagon receptor antagonist-9 Antagonist / Unkown
HY-118914 Glucagon receptor antagonist inactive control Control / Unkown
Bioactive MoleculesInhibitory Antibodies (3)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P990013 Gulgafafusp alfa Inhibitor 95.481% Unkown
HY-P991099 Anti-GLP1R Antibody Inhibitor 97.19% Unkown
HY-P992006 Anti-Glucagon Antibody Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Felis catus GCGR VGNC VGNC:62492
Bos taurus GCGR VGNC VGNC:29285
Canis familiaris GCGR VGNC VGNC:41144
Rattus norvegicus GCGR RGD RGD:2669
Macaca mulatta GCGR VGNC VGNC:72899
Mus musculus GCGR MGD MGI:99572
Others GCGR NCBI